The effects of antiproliferative drugs at stenotic area associated with primary atherosclerotic lesions in apoE knockout mouse - Change of vascular remodeling.
10.4070/kcj.2000.30.4.517
- Author:
Hong Seog SEO
;
Eun Mi LEE
;
Jeong Cheon AHN
;
Soo Mi KIM
;
In Hee HWANG
;
Kyo Seung HWANG
;
Woo Hyuk SONG
;
Do Sun LIM
;
Chang Gyu PARK
;
Young Hoon KIM
;
Wan Joo SHIM
;
Dong Joo OH
;
Young Moo RO
- Publication Type:Original Article
- Keywords:
apolipoprotein E deficient mouse;
Atherosclerosis;
Vascular remodel;
Primary prevention
- MeSH:
Animals;
Aorta;
Apolipoproteins;
Apolipoproteins E*;
Atherosclerosis;
Cilazapril;
Constriction, Pathologic;
Diltiazem;
Humans;
Infant;
Methotrexate;
Mice;
Mice, Knockout*;
Molsidomine;
Popliteal Artery;
Primary Prevention;
Probucol;
Trimetazidine
- From:Korean Circulation Journal
2000;30(4):517-527
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Apolipoprotein (apo) E deficient mouse can produce reproducible fixed stenotic primary atherosclerotic lesion, which reveals failure to remodel of vascular lumen, in the ascending aorta, external carotid, common carotid, iliac, femoral and popliteal arteries. To evaluate the effect of drugs in regarding to both prevention of primary atherosclerotic lesion and vascular remodeling, a systematic analysis of distribution of atherosclerotic lesions was undertaken in chow-fed, 9-momth-old apo E deficient mice, which was administrated drugs including asprin, methotrexate, probucol, sulodexide, diltiazem, cilazapril, trimetazidine, molsidomine, pentoxiphylline and Ginexin (R) for 7 month from 3 month-old. On gross and microscopic examination, formation of primary atheroscleotic lesions could be delated and/or prevented patially by effets of these drugs. On morphometric examination, failure to remodel forming vascular stenosis could not be seen, though relatively mild atherosclerotic lesion occured at vascular tree. These data suggest that the stenotic process in advanced atherosclerotic vessels can be delayed and/or prevented by several drugs including methotrexate, probucol, sulodexide, diltiazem, cilazapril, trimetazidine, molsidomine, pentoxiphylline and Ginexin (R) in vivo state.
